New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Scott Solomon, MD
Mikhail Kosiborod, MD
Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target
Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Erin Michos
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
CETP inhibition: Lessons from two decades of clinical trials
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
Managing hypertrophic cardiomyopathy in clinical practice: The patient journey
Perry Elliott, MD
Roberto Barriales-Villa, MD, PhD
Iacopo Olivotto, MD
Updates From the 7th World Symposium Task Force
Eric D. Austin, MD, MSCI
Hilary M. DuBrock, MD
H. James Ford, MD
Gustavo A. Heresi, MD, MS
Gergely Meszaros, JD, MSc
Oksana A. Shlobin, MD
Ioana Preston, MD
Lucilla Piccari, MD, PhD
What are the challenges in making the right diagnosis in HCM?
Understanding the etiology of HCM and pathways for intervention
The clinical challenge of managing a patient with HCM
Optimizing Care for Patients with CKM Syndrome: A Multidisciplinary Approach
Jürgen Floege, MD
Muthiah Vaduganathan, MD, MPH
Definition and Staging of CKM Syndrome
Screening for CKM Syndrome
Comprehensive Management of Individuals with CKM Syndrome
Muthiah Vaduganathan, MD
Case-Based Learning and Future Directions
Jurgen Floege MD
Bridging the Gap: ns-MRAs in Cardiovascular-Kidney-Metabolic Syndrome Care
Pardeep Jhund, MD, PhD
Hiddo L. Heerspink, PhD
John McMurray, MD
Akshay S. Desai, MD
Csaba P. Kovesdy, MD
Finnian R. McCausland, MD
Orly Vardeny, MD
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.